OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Teams Up With CFN Media

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP)

OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has engaged the services of CFN Media as part of an effort that seeks to attract high-quality investors. The company also plans to use the partnership to broaden its product’s target market.

CFN Media Agreement

CFN Media will conduct a 2-month investor and market visibility program as part of the agreement. The company’s President, Frank Lane, has welcomed the partnership, which he says will help millions of people gain access to their high-quality cannabinoid psoriasis cream. The Israel-based company plans to use its presence in the cannabinoid sector to promote OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) offerings.

“We are very excited to cooperate, again, with CFN Media. In the near future, OWC will report developments that we believe are material. CFN has proven themselves as a reliable and professional media outlet with exceptional editorial skills. Together with their video interviews we will have the best channel to convey our message to the investment community,” said OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) CEO, Mordechai Bignitz.

CFN Media’s collaboration builds on a similar agreement signed with Mediq Innovation partners last month. Under the items of that agreement, the German-based company has agreed to market OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) products in Europe.

Mediq’s will offer both strategic and scientific assistance geared towards developing a commercial market for OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) proprietary cannabinoid products. Plans are already underway to unveil products in Germany since the country’s law and regulations allow for the sale of non-smokable cannabis.

Europe Push

Germany’s health care sector will be key for growth as it offers reimbursement for medical cannabis. Other countries where cannabis has a legal status do not yet offer reimbursement for cannabinoid treatment(s). Scientific collaboration should also benefit the company as it continues to explore new products in a bid of taking advantage of growing demand for cannabis products.

“We’re looking forward to initiating our efforts on behalf of OWCP in Europe, starting in our home market of Germany. Since German laws and regulations allow non-smokable forms of medical cannabis, we believe that OWCP’s proprietary cannabinoid-based topical psoriasis cream is the right product at the right time,” said Mediq Managing Director, Jan Wende.

Separately, OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) has confirmed that its wholly owned Israeli subsidiary, One World Cannabis Ltd, has designed the road map for a Multiple Myeloma study. The study builds on promising results from an earlier vitro study. The purpose of the next phase of study is to investigate the dose levels and delivery systems for a future planned study on human patients.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OWCP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

TrovaGene Inc (NASDAQ:TROV) Signs Agreement with AstraZeneca (AZN)

TrovaGene Inc (NASDAQ:TROV)

TrovaGene Inc (NASDAQ:TROV) has announced entering into an agreement with AstraZeneca plc (ADR) (NYSE:AZN) that will see the latter supply Trovera® urine ctDNA biomarker tests and services. TrovaGene Inc is a precision medicine biotechnology company.

Initially, the Trovera® EGFR urine liquid biopsy test will be applied in an open label prospective biomarker trial to evaluate whether the collective use of noninvasive testing i.e. blood and urine testing are as effective and reliable as tissue testing in identifying the mutation status of the epidermal growth factor receptor (EGFR) T790M.

In a statement, TrovaGene Inc (NASDAQ:TROV) Chief Executive Officer, Bill Welch, said they are pleased to work AstraZeneca and to have their urine liquid biopsy test incorporated in a trial intended to explore new and non-invasive means of detecting the EGFR mutation.

TrovaGene Inc (NASDAQ:TROV) offers CLIA laboratory testing services for several clinical research third parties and biopharmaceutical companies. It is this expertise that has supported the development of biomarkers for PCM-075, a polo-like kinase 1 (PLK1) inhibitor. The company intends to use an acute myeloid leukemia (AML) genetic panel to evaluate the response to PCM-075 in its phase 1/2 trial.

Recently AstraZeneca got the US Food and Drug Administration for its Tagrisso (osimertinib) used in the treatment of metastatic EGFR T790M mutation-positive non-small cell lung cancer.

Additionally, AstraZeneca recently announced getting marketing approval from the Drug Controller General of India (DCGI) for asthma drug Symbicort. According to the company, Symbicort is a non-variable dose drug combination made of formoterol fumarate and budesonide dehydrate which are administered through a special device. The drug is meant for treatment of severe asthma as well as patients with severe chronic obstructive pulmonary disease (COPD) and who have a history of exacerbations.

Symbicort has been approved for use in asthma and COPD treatment in 910 countries. According to two major studies, the addition of budesonide to formoterol led to improvement in asthma symptoms and lung function in addition to reducing exacerbation.

Additionally, in two one-year clinical studies in patients suffering from COPD, Symbicort exhibited superior to placebo, formoterol, and budesonide in regards to lung function in addition to registering reduction in the rate of exacerbation as compared to formoterol and placebo.

TrovaGene Inc (NASDAQ:TROV) surged 37.36% and closed at $1.30 in Thursday’s trading session.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TROV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) To Cut Costs After Q1 Net Loss

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has embarked on a cost-cutting drive after reporting a wider than expected first-quarter net loss of (-$8.3) million. The exoskeleton developer plans to streamline its operations and cut its workforce by about 25% in a bid to reduce cash burn.

Cost-Cutting Drive

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) expects the cuts to result in a 25% reduction in monthly operating expenses. Cash severance and related expenses as a result of cutbacks could rise to $1 million. The cost-cutting drive will not interfere with the company’s research and development activities geared towards advancing proprietary solutions.

The restructuring comes at a time when Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) is looking for ways to fuel sales on its lead product Ekso GT – among other exoskeleton offerings. In a bid to push for sales in industrial markets, the company is currently working with partners to increase awareness.

“We remain on track with our strategic priority of establishing our unique products as the industry standard. We believe that the measures announced today will enhance shareholder value as we more efficiently deploy cash and solidify our leadership in the emerging exoskeleton industry,” said CEO Thomas Looby

A decline in revenues from $8.5 million as of last year to $1.4 million in Q1 2017 is a major point of concern. However, the chief executive officer remains confident that positive feedback will lead to greater success as they ramp up commercialization efforts.

Strategic Collaborations

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) has already teamed up with four leading rehabilitation centers as part of an effort that seeks to expand the current target market. The four centers that the company is collaborating with are Barrow Neurological Institute, Good Shepherd Rehabilitation Network, Marianjoy Rehabilitation Hospital, part of Northwestern Medicine and Villa Beretta” Centro di Riabilitazione, Costa Masnaga (LC), Italy

The collaborations should advance the use of the company’s innovative exoskeleton in mobility-impaired patients. Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) also expects the collaboration to help build clinical support on the benefits of its products. Each center will also help research and development efforts.

“We are proud to work with these visionaries who are dedicated to helping patients with recovery and to provide quantifiable insights into the strides they’re making walking with an exoskeleton,” said Mr. Looby.

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) stock was down by 9% in Friday’s trading session to end the week at $1.92 a share. In early Monday trading, EKSO shares are trading down a further 7%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EKSO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Sorrento Therapeutics Inc. (NASDAQ:SRNE)’s CEO off the Hook

Sorrento Therapeutics Inc. (NASDAQ:SRNE)

Sorrento Therapeutics Inc. (NASDAQ:SRNE) has confirmed the dismissal of claims lodged by Wildcat Capital Management. The investment firm whose clients own 6.5% of the company’s common stock was pushing for the dismissal of Chief Executive Officer, Henry Ji.

Wildcat Management Demands

In a letter sent to Sorrento Therapeutics Inc. (NASDAQ:SRNE) board, Wildcat Management cited destruction of shareholder value as the reason behind their demands. The firm accuses the current CEO of repeatedly transferring assets to newly created subsidiaries and then granting executives and non-employee directors stock options at nominal prices.

“The Wildcat Shareholders believe that the Company’s Chief Executive Officer (“CEO”), Dr. Henry Ji, has consistently acted in a manner that is not in the best interests of shareholders and has destroyed significant shareholder value. Further, the Wildcat Shareholders believe that the Company’s Board of Directors (the “Board”) has failed to act in the best interests of shareholders and that the Directors have breached their fiduciary duties,” Wildcat wrote in a letter to the board.

The firm had also raised concerns about a number of financing transactions that the executive had spearheaded, saying they had significantly diluted shareholders value. Wildcat Capital Management was also pushing for the appointment of its three nominees into the board to oversee the interest of its clients.

ZTildo Positive Results

Separately, Sorrento Therapeutics Inc. (NASDAQ:SRNE) subsidiary SCILEX Pharmaceutics has reported positive results in a head to head adhesion study of lead product ZTildo. The company says the product demonstrated superior adhesion compared to Varsities, a reference product approved in Europe. ZTildo is a non-opioid lidocaine patch being developed for the treatment of post-herpetic neuralgia, a neuropathic condition.

The positive study results, according to Sorrento Therapeutics Inc. (NASDAQ:SRNE), complement previous clinical and adhesion data results that should help support their case for new drug application.

“We are pleased to report our noteworthy data. We believe that the ability of ZTildo™ to outperform Varsities® in this head to head study will translate into better patient compliance and provide us with an important clinical advantage. I look forward to moving ZTildo™ closer to commercialization in the US and the EU,” said president SCILEX, Anthony Mack.

Chief executive officer believes the positive study results not only validate ZTildo but should go a long way in supporting product development efforts. The executive expects the head to head study to help bolster ZTildo prospects as they move to pursue sales opportunities in Europe and the U.S.

Sorrento Therapeutics Inc. (NASDAQ:SRNE) stock was up by 8.11% in Friday trading session to end the week at $2 a share. SRNE shares are unchanged in early Monday trading.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SRNE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Investors Skeptical on Envision Solar International, Inc. (OTCMKTS:EVSI)

Envision Solar International, Inc. (OTCMKTS:EVSI)

Envision Solar International, Inc. (OTCMKTS:EVSI) has been getting hammered over the past month – losing over 36% while the S&P 500 gained about 1%. The price action is curious given Envision’s April financial release for FY2016, which showed that the green energy company had increased revenues for the third year in a row. (Supplemental note – The company’s most recent SEC financial filing, in April, showed a quarterly improvement in revenues and a shrinking net loss figure.)

Desmond Wheatley, CEO of Envision Solar International, Inc. (OTCMKTS:EVSI) commented on the annual results “We are executing on our plan. The growth markets we address are recognizing the unique value in our products and we are seeing increased sales year after year. I believe that we are very well positioned to see increasing and accelerating growth in 2017.”

Envision Solar International, Inc. (OTCMKTS:EVSI) operates in three specific verticals – electric vehicle (EV) charging, media, branding systems, and energy security. Since the April filing, there has been a rash of good news out of the company. Envision successfully deployed its EV chargers in a Buffalo, NY nature preserve; they received a multi-year award from New York city for their EV chargers; Fresno County unveiled a county-wide EV charging program using Envision’s solar powered EV chargers; Maywood, CA deployed Envision technology; and most recently the city of Santa Monica announced that it will deploy Envision Solar International, Inc. (OTCMKTS:EVSI)’s EV ARC product to provide free EV charging as well as emergency power.

Envision has a market-cap of only $11.8 million. For such a small firm, all of this good news should have propelled its stock price, not placed it under pressure. So why has EVSI lost over a third of its share value in a stable market? No news exists that could justify a lower valuation. This is definitely a green energy stock that deserves close, and constant, attention as new information could confirm either a logical explanation for the lower valuation, or a buying opportunity.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EVSI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Abeona Therapeutics Inc (NASDAQ:ABEO) Receives FDA Orphan Drug Designation

Abeona Therapeutics Inc (NASDAQ:ABEO) Receives FDA Orphan Drug Designation

Abeona Therapeutics Inc (NASDAQ:ABEO) has announced receiving an Orphan Drug Designation (ODD) from the U.S. Federal Drug Administration (FDA) for its EB-101 gene therapy targeting dystrophic epidermolysis bullosa (DEB) patients. This also includes recessive dystrophic epidermolysis bullosa (RDEB), a deadly genetic skin disorder characterized by lesions and skin blisters. Abeona specializes in the development of gene therapies for treatment of life-threatening diseases.

In a statement, Abeona Therapeutics Inc (NASDAQ:ABEO) President & CEO, Timothy J. Miller, Ph.D said Abeona’s main agenda is to develop therapies to address the huge unmet demands from patients suffering from dystrophic epidermolysis bullosa. He added that they highly grateful for the new designation and the recognition of EB-101 by FDA as a rare product which will offer much needed therapeutic benefits to patients suffering from dystrophic types of epidermolysis bullosa among them RDEB. EB-101 is the company’s third gene therapy to be given the Orphan Drug Designation by the FDA that, as Miller states, is an important driver to the company’s program as it offers seven years of therapies for the same indications.

Wounds that appear on patients with RDEB, referred to as “butterfly skin” syndrome, can go unhealed for several months or even years as a result of the inability of the skin to remain attached to the dermis below and can spread over a large part of the body. During the Phase 1/2 clinical study, EB-101 was used to treat non-healing chronic wounds on each patient and examined the process of healing at particular time intervals over years. The clinical trial’s endpoint examined the safety as well as evaluating the healing process and compared the results to control untreated wounds. The secondary endpoint of the trial includes collagen C7 as well as the restoration of anchoring fibrils after three and six months of post-treatment.

EB is a class of deadly genetic skin diseases which leads to growth of erosions and blisters on the skin and spreads over the entire body. The most deadly is the epidermolysis bullosa (RDEB), which is known for open and painful wounds, skin blistering, esophageal strictures, joint contractures, corneal abrasions, pseudosyndactyly and a shortened life span. Patients suffering from RDEB have a shortage of type VII collagen (C7) as a results of gene mutations in the gene COL7A1 which encodes for C7 and the main element of anchoring fibrils, which make the connection between the dermis and the epidermis.

Abeona Therapeutics Inc (NASDAQ:ABEO) closed Thursday’s session at $4.75 losing 4.04%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ABEO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Re-acquires Belbuca

BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been on an upward trend after reporting Q1 2017 earnings that beat estimates. Reacquisition of license rights to pain the management product, Belbuca, continues to fuel investor’s sentiments on the stock.

Stellar Q1 Earnings

The pain management product remains a key driver of the company’s earnings. During the first quarter, the drug generated sales that propelled BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to profitability. First quarter net income came in at $48.3 million or $0.58 cents a share, blowing away analysts’ earnings expectations of $0.09 cents a share.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Chief Executive Officer, Mark Sirgo, expects revenue and earnings growth to continue into the second half of the year.

“We completed a swift and effective transition of BELBUCA following the early January close of the transaction with Endo Pharmaceuticals (Endo), and by the end of the quarter, we were generating sufficient product revenue to offset the expense of our commercial business unit. In fact, we recorded the highest net sales revenue for BELBUCA since the product was launched over a year ago…,” said Mr. Sirgo.

BioDelivery Sciences reported net revenues of $29.5 million for the first quarter, compared to net revenue of $3 million reported last year. Belbuca accounted for $4.6 million of total revenues. The company would have earned $640,000 in royalty payments from the drug had it not reacquired it. Cash and cash equivalent as of the end of the first quarter totaled $35.2 million compared to $32 million as of December 31, 2016.

Growth Drivers

The specialty pharmaceutical company is currently pursuing licensing agreements for Belbuca as it continues to pursue new sales avenues. The company is also eyeing approval in Canada to supplement sales in the U.S. Early this year the company secured $75 million in financing that it plans to use for the commercialization of the drug.

Belbuca is not the only product that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is relying on for revenues. Bunavail is the company’s other lead product and it generated revenues of $3.2 million in the quarter, up from $2.1 million as of last year.

“As for BUNAVAIL®, we will continue to focus our efforts on our current prescribers while working to secure new managed contracts where BUNAVAIL is in a favorable position. BUNAVAIL generated $3.2 million in revenue for the quarter,” said Mr. Sirgo.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) plans to make a regulatory submission later in the year for the manufacture of ONSOLIs, a drug it licensed to Collegium Pharmaceuticals in 2016

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) closed a $2.30 on volume of 213,882.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BDSI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

NewLink Genetics Corp (NASDAQ:NLNK) Plunges After Genentech Withdrawl

NewLink Genetics Corp (NASDAQ:NLNK)

NewLink Genetics Corp (NASDAQ:NLNK) stock plunged after the company announced the termination of a licensing agreement with Genentech for its IDO inhibitor, GDC-0919,. However, the termination will not affect research collaboration on the discovery of other IDO/TDO inhibitors between the two firms.

GDC-0919 Disappointing results

Genentech’s decision came as a surprise, given that data on the inhibitor was recently presented at the American Society of Clinical Oncology annual meeting. The two companies had signed the licensing agreement in 2014.

NewLink Genetics Corp (NASDAQ:NLNK) stock shed more than a third of its market value on Genentech ending its collaboration on GDC-0919 development. Disappointing clinical trial results appears to have triggered the surprise move by Genentech. The trial of GDC-0919 in combination with Roche’s –PD-L1 failed to yield the desired results.

Clinical Trial results indicate that the response rate for GDC-0919 stood at 9% in patients with solid tumor cancers. The response rate was quite low to justify further clinical research. Epacadostat, a drug being marketed by Incyte Corporation (NASDAQ:INCY), delivered a response rate of 30-35% when combined with Merck & Co., Inc. (NYSE:MRK) PD-L inhibitor.

Even on the disappointing results CEO, Charles Link, remains optimistic about GDC-0919 prospects.

“We are obviously disappointed in this decision. We remain committed to advancing our IDO pathway inhibitor indoximod, which continues to generate exciting data in combination with anti-PD-1 agents, cancer vaccines, and chemotherapy in multiple cancer types including melanoma, prostate cancer, acute myeloid leukemia, and pancreatic cancer,” said Mr. Link.

Genentech returning rights of GDC-0919 caps another setback on NewLink Genetics Corp (NASDAQ:NLNK)’s push to build out its pipeline of oncology drugs. Early this month the biopharmaceutical company announced that one of its IDO-inhibitors had failed in a mid-stage breast cancer trial. The negative results prevents the company from expanding its usage beyond melanoma treatment.

NewLink Genetics Corp (NASDAQ:NLNK) stock remains under pressure as a wave of negative results on the clinical trial front continues to spook investors. NewLink Genetics Corp (NASDAQ:NLNK) stock was up by 1.30% in Wednesday’s trading session, to end the day at $6.22 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NLNK and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) Acquiring Hempco Food and Fiber

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF)

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) plans to expand its footprint in the cannabis business with the acquisition of a 19.9% stake in Hempco Food and Fiber. The Canadian company is currently in discussions with the company’s owners as it eyes a majority stake.

Hempco Acquisition

Acquiring a controlling stake in Hempco comes at a time when the cannabis industry is experiencing rapid growth. Hempco acquisition should expand AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF)’s product portfolio and give it a competitive edge in the multibillion industry.

Hempco continues to grow at an impressive rate. The company recently posted a 136% increase in revenues, helped by a diversified product line that includes packaged food products, Hemp fiber, and nutraceuticals. A growth in demand for Hemp products has prompted the company to expand its production facility as it looks to double its current capacity of about 225,000 kg per month.

“Hempco is a rapidly expanding company with a strong and broadly diversified product offering, across a variety of health-related markets. Leveraging our relationship with extraction leaders, the potential to develop a high-volume, low-cost source for CBD-based products creates significant upside potential, making this transaction particularly attractive,” said Aurora CEO, Terry Booth.

A merger with Aurora according to Hempco CEO, Charles Holmes, will open doors for new resources needed to fuel commercial development. The executive also expects the company’s strong brand to strengthen their competitive edge in the race for market share.

Aurora Loan

In a bid to bolster Hempco prospects in the Hemp business, Aurora has agreed to loan the company $750,000 at an interest rate of 8%. The loan is to be repaid before June 8, 2019. Aurora has also agreed to participate in a private placement with Hempco for the acquisition of 10,558,676 units. Each unit is priced at $0.3075 and consists of one share and Warrant for the purchase of additional shares.

Separately, AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) has confirmed the appointment of Allan Cleiren as its new Chief Operational Officer. He joins the company with three decades of leadership experience in finance and operations management. Mr. Cleiren is tasked with the responsibility of pursuing future opportunities as well as ensuring seamless integration of domestic and international acquisitions.

AURORA CANNABIS IN COM NPV (OTCMKTS:ACBFF) stock was down by 0.19% in Wednesday’s trading session to end the day at $1.61 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ACBFF and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

Freeze Tag, Inc. (OTCMKTS:FRZT)’s Garfield Go Game Debuts

Freeze Tag, Inc. (OTCMKTS:FRZT)

Freeze Tag, Inc. (OTCMKTS:FRZT)’s much awaited augmented reality treasure hunting game is now available in Apple Inc. (NASDAQ:AAPL)’s App Store and Alphabet Inc.(NASDAQ:GOOGL)’s Play Store. The company is currently targeting gamers in the U.S, Canada, and Australia. Plans are underway to make the game available in more countries. The game is based on the beloved comic strip of Garfield, created in 1978.

Garfield Go Basics

Just like Pokémon Go, Garfield Go accords players an opportunity to search for hidden treasures in the real world. The location-based game comes with the iconic Garfield character in addition to millions of treasure locations and real money prizes.

The game requires people to locate coins after being allowed to enter ‘Augmented Reality’ mode to search for treasure locations. To be able to find the hidden treasures, gamers will have to feed Garfield his favorite foods to unlock treasure hunts.

“Garfield GO! Is the first augmented reality, location-based game that features the beloved Garfield cat character. It’s like Pokémon GO, but with Garfield, the lasagna-loving cat. We are launching the game in Australia to gather player feedback and refine the experience before we launch in the USA and other parts of the world,” said CEO Craig Holland.

Garfield Go Competitive Edge

Freeze Tag, Inc. (OTCMKTS:FRZT) is looking to differentiate itself from other players gunning for market share in the fast-growing augmented reality gaming space with a number of exciting features. Real money prizes are one of the many aspects of the game that the company believes will help draw in more players. The company has also unlocked millions of treasure locations and dozens of Garfield comic strip pieces to keep people engaged.

Over 100 badges are up for grabs for each achievement, in addition to funny hats that change and customize Garfield appearances. Hilarious animations, voice recordings and sound effects from the main character are also on offer.

Garfield Go was developed in collaboration with Munzee. The partnership has helped build out the geographic play areas for the game with the inclusion of Munzee locations.

Freeze Tag, Inc. (OTCMKTS:FRZT) has been moving higher in the market as investors remain optimistic that this augmented reality game will have a similar impact as achieved by Pokémon Go. However, the company faces an uphill task to de-throne some titles in the industry that have accrued a substantial amount of market share. In Wednesday’s trading session the stock was up by 11.84%, ending the day at $0.0085 a share.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $FRZT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Ruchi has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.